

Thursday 29th September 2016

Translational Research Programme

Hilton Meeting Rooms 1 – 6

09:30-10:50 Session 1: Acute coronary syndromes
Chairs: Bianca Rocca, Agneta Siegbahn

- 09:30 New directions in atherothrombosis research - Lina Badimon
- 09:50 Leukocytes and thrombogenesis: current knowledge and gaps in knowledge - Walter Speidl
- 10:10 Frontiers in genetics and biomarkers in acute coronary syndromes - Lars Wallentin
- 10:30 Anti-inflammatory drugs and acute coronary syndromes - Carlo Patrono

10:50-11:10 **Coffee break**

11:10-12:30 Session 2: Antiplatelet therapy
Chairs: Thomas Weiss, Bianca Rocca

- 11:10 Is there a therapeutic window of platelet inhibition for elective PCI? - Daniel Aradi
- 11:30 Platelet function testing for timing of CABG surgery: useful or not? - Jean-Philippe Collet
- 11:50 Pros and cons of bridging to CABG surgery - Kurt Huber
- 12:10 Pleiotropic effects of P2Y₁₂ inhibitors - Mark Thomas

12:30-14:00 **Lunch and Exhibition**

12:45-13:45 **Lunchtime symposium** (*Monarch Suite Lecture Theatre*)
- Critical decision making in antiplatelet management post MI
This is an AstraZeneca funded and organised promotional meeting

14:00-15:20 Session 3: Diabetes and obesity
Chairs: Gemma Vilahur, Harald Arnesen

- 14:00 Adipose tissue linking inflammation and thrombosis - Lina Badimon
- 14:20 Lifestyle interventions for modifying atherothrombotic risk - Ingebjorg Seljeflot
- 14:40 Prothrombotic effects of hypoglycaemia - Ramzi Ajjan
- 15:00 How important is endothelial and microvascular function? - Filippo Crea

15:20-15:50 **Coffee break and posters**

15:50-17:10 Session 4: Mechanisms of thrombosis and thrombotic risk
Chairs: Ingebjorg Seljeflot, Walter Speidl

- 15:50 Microparticles in thrombogenesis - Agneta Siegbahn
- 16:10 The role of neutrophils in atherothrombosis - Gemma Vilahur
- 16:30 MicroRNAs and platelet reactivity - Manuel Mayr
- 16:50 Platelet turnover and platelet reactivity: what's new? - Erik Grove

17:15-17:45 Plenary lecture (*Monarch Suite - Lecture Theatre*)
- New frontiers in acute stroke management - L.J. Kappelle

This Plenary lecture is sponsored by MSD. MSD has had no input into the choice of speaker or topic discussed during this lecture.



Lunchtime Symposium

Day 1

Monarch Suite Lecture Theatre

12:45-13:45

Critical decision making in antiplatelet management post MI

Co-chairs Pr Robert Storey & Pr Stefan James

Welcome and introduction

How coronary angiography findings impact on residual risk assessment

- Dr Iqbal Javaid

Translating PEGASUS - TIMI 54 to clinical practice:

- **The cardiologist's perspective** - Pr Robert Storey

- **The GP's perspective** - Pr Ahmet Fuat

Close and conclusion

(This is an AstraZeneca funded and organised promotional meeting)



Friday 30th September 2016

Translational Research Programme

Hilton Meeting Rooms 1 – 6

09:20-10:40 Session 5: Atrial fibrillation and anticoagulant therapy
Chairs: Harald Arnesen, Diana Gorog

- 09:20 Biomarkers for determining thromboembolic risk in AF - Agneta Siegbahn
- 09:40 Upstream or downstream thrombin inhibition – does it matter? Yes - Christoph Bode
- 09:55 Upstream or downstream thrombin inhibition – does it matter? No - Hugo ten Cate
- 10:10 Panel discussion - All
- 10:25 Potential new targets for anticoagulant therapy - Bernd Jilma

10:40-11:10 Coffee break and posters

11:10-12:30 Session 6: Bleeding risk and antidotes – joint session with ESC Working Group on Cardiovascular Pharmacotherapy
Chairs: Stefan Agewell, Bianca Rocca

- 11:10 Pharmacological strategies for limiting bleeding risk in ACS - Sven Wassmann
- 11:30 Bleeding risk scores in ACS: helpful or unhelpful? - Pascal Vranckx
- 11:50 Bleeding and ischaemic risk: new insights - Gregory Ducrocq
- 12:10 Progress with antidotes to antithrombotics - Alexander Niessner

12:30-14:00 Lunch and Exhibition

12:45-13:45 Lunchtime symposium (*Monarch Suite Lecture Theatre*)
- How biomarkers support improved cardiovascular disease management
This is a Roche sponsored symposium.

14:00-15:20 Session 7: Controversies in antithrombotic therapy
Chairs: Lars Wallentin, Jolanta Siller-Matula

- 14:00 Prasugrel or ticagrelor in STEMI? - Stefan James
- 14:15 Pretreatment with P2Y₁₂ inhibitors in NSTEMI-ACS (PRO) - Dietmar Trenk
- 14:30 Pretreatment with P2Y₁₂ inhibitors in NSTEMI-ACS (CON) - Johanne Silvain
- 14:45 Panel discussion - All
- 15:00 Do we still need warfarin for non-valvular AF? - Harald Arnesen

15:20-15:50 Coffee break and posters

15:50-17:10 Session 8: Venous thromboembolism
Chairs: Diana Gorog, Rhona Maclean

- 15:50 Is inflammation the common link between arterial and venous thrombosis? - Hugo ten Cate
- 16:10 Management of idiopathic VTE - Henri Bounameaux
- 16:30 Fibrinolysis for DVT: what evidence? - Per Morten Sandset
- 16:50 Thrombolysis for intermediate risk PE - Mareike Lankeit

19:00 Conference reception - Home House

Lunchtime Symposium

Day 2

Monarch Suite Lecture Theatre

12:45-13:45

Roche Lunchtime Symposium:

“How biomarkers support improved cardiovascular disease management”

Co-chairs: Prof. Dr. Dirk Sibbing (München, Germany),
Dr. Daniel Aradi (Balatonfüred, Hungary)

12:45-13:05

Utility of cTnT-hs and GDF-15 in selection of invasive versus a non-invasive strategy in NSTEMI-ACS

- Prof. Dr Lars Wallentin, (Uppsala, Sweden)

13:05 - 13:25

Monitoring platelet function in clinical practice – focus on PCI-treated patients

- Prof. dr Dirk Sibbing (München, Germany)

13:25 - 13:45

The novel biomarker-based ABC-bleeding risk score for patients with atrial fibrillation

- Dr Ziad Hijazi, (Uppsala, Sweden)

This is a Roche sponsored symposium.



Saturday 1st October 2016

Young Thrombosis Researchers Group annual meeting, Late-breaking science and oral abstract presentations & Challenging cases

Monarch Suite Lecture Theatre

08:30-09:30	Young Thrombosis Researchers Group annual meeting
09:30-11:00	<u>Session 9: Late-breaking science and oral abstract presentations</u> <u>Chairs: Johann Wojta, Erik Grove</u>
09:30-09:45	Twice daily dosing normalizes the impaired antiplatelet effect of low-dose aspirin due to enhanced platelet turnover in patients undergoing on-pump cardiac surgery - Benedetta Porro
09:45-10:00	Platelet reactivity and outcomes after transcatheter aortic valve implantation - Lisa Gross
10:00-10:15	A clinical risk score to identify patients at high risk of very late stent thrombosis benefitting from prolonged dual antiplatelet therapy - Marieke Gimbel
10:15-10:30	Dyslipidemia associated oxidized LDL impairs inhibitory cAMP signalling through a CD36 dependent activation of PDE3A - Martin Berger
10:30-10:45	Cancer Incidence And Mortality With Thienopyridines: A Systematic Review and Meta-Analysis - Rafail Angelos Kotronias
10:45-11:00	Patient-independent variables affecting the assessment of aspirin responsiveness by serum thromboxane measurement - Alessandro Rizzi
11:00-11:30	Coffee break and posters
11:30-12:30	<u>Session 10: Challenging cases</u> <u>Chairs: Mark Thomas, Thomas Weiss</u>
11:30-11:45	Management of life-threatening haemorrhage in patient with recent left main coronary angioplasty - Rui Azevedo Guerreiro
11:45-12:00	Concurrent Massive Pulmonary Embolism and Anterior ST - Joseph Marc Seguban
12:00-12:15	Triple therapy in a young patient with antiphospholipid syndrome after ST elevation myocardial infarction - Domagoj Mišković
12:15-12:30	Management of Anticoagulation in Acute Pulmonary Embolism and Stanford type B Aortic Dissection - Joana Simmões
12:30-12:45	<u>Presentation of prizes and closing remarks</u> <u>Chairs: Robert Storey, Bianca Rocca</u>
12:45-13:45	Lunch